medigraphic.com
Organo Oficial de la Sociedad Mexicana de Urología

2012, Number 2

<< Back Next >>

Rev Mex Urol 2012; 72 (2)

Testicular function in postchemotherapy patients with testicular cancer

Fernández-Noyola G, Martínez Á, Ahumada-Tamayo S, Santana-Ríos Z, Fulda-Graue S, Urdiales-Ortiz A, Pérez-Becerra R, García-Salcido F, Camacho-Castro A, Muñoz-Ibarra E, Osornio-Sánchez V, Mayorga-Gómez E, Garza-Sainz G, Cantellano-Orozco M, Morales-Montor G, Martínez-Arroyo C, Pacheco-Gahbler C

Language: Spanish
References: 22
Page: 56-62
PDF size: 396.59 Kb.


ABSTRACT

Introduction: Testicular cancer represents 5% of all urologic tumors and its treatment involves a multidisciplinary approach with repercussions on testicular function because adjuvant treatment is not selective for neoplastic cells and therefore has a profound impact on reproductive and hormonal function.
Objective: To study the testicular function of patients with testicular cancer that received adjuvant chemotherapy management at the Hospital General Dr. Manuel Gea González.
Material and methods: An ambispective review was carried out using 130 case records from the hospital urology service database. Patients were grouped according to the number of chemotherapy cycles received and sperm evaluation results were recorded before and after adjuvant treatment and a hormonal profile was also carried out.
Results: Spermatogenesis deterioration at the time of testicular cancer diagnosis was found in 50% of the cases. After chemotherapy, 67.5% of the patients presented with reproductive function alteration. Changes in hormonal function were less frequent than in reproductive function.
Conclusions: Reproductive function in post-chemotherapy testicular cancer patients is related to reproductive function status prior to adjuvant treatment and to the number of cycles received.


REFERENCES

  1. Ahmedin J, Freddie B, Center MM, et al. Global cancer statistics. CA Cancer J Clin 2011;61:69-90.

  2. Camarena H, Ariza P, Mata MP, et al. Análisis de sobrevida en cáncer de testículo en 18 años. Rev Mex Urol 2008;68:262-267.

  3. Brydøy M, Fossa S, Klepp O. Paternity and Testicular Function Among Testicular Cancer Survivors Treated With Two to Four Cycles of Cisplatin-Based Chemotherapy. Eur Urol 2010;58:134-140.

  4. Jacobsen D, Theodorsen L, Fossa D, et al. Spermatogenesis after unilateral orchiectomy for testicular cancer in patients following surveillance policy. J Urol 2001;165:93-96.

  5. Spermon JR, Ramos L, Wetzels AM, et al. Sperm integrity pre- and postchemotherapy in men with testicular germ cell cancer. Hum Reprod 2006;21:1781-1786.

  6. Huyghe E, Matsuda T, Daudin M, et al. Fertility after testicular cancer treatments: results of a large multicenter study. Cancer 2004;100:732-737.

  7. Kim C, McGlynn KA, McCorkle R, et al. Fertility among testicular cancer survivors: a case-control study in the U.S. J Cancer Surviv 2010;4:266-273.

  8. Huddart RA, Norman A, Moynihan C, et al. Fertility, gonadal and sexual function in survivors of testicular cancer. Br J Cancer 2005;93:200-207.

  9. Pectasides D, Pectasides E, Papaxoinis G, et al. Testicular function in poorrisk nonseminomatous germ cell tumors treated with methotrexate, paclitaxel, ifosfamide, and cisplatin combination chemotherapy. J Androl 2009;30:280-286.

  10. Albers P, Albrecht W, Algaba F, et al. Guidelines on testicular cancer, EAU 2011. European Urology 2011;60:304–319.

  11. Motzer R, Agarwal N, Beard C. NCCN Guidelines Testicular cancer 2011. J Natl Compr Canc Netw 2009;7:672-693.

  12. Brennemann W, Stoffel-Wagner B, Helmers A, et al. Gonadal function of patients treated with cisplatin based chemotherapy for germ cell cancer. J Urol. 1997 Sep;158(3 Pt 1):844-850.

  13. Petersen PM, Hansen SW, Giwercman A, et al. Dose dependent impairment of testicular function in patients treated with cisplatin-based chemotherapy for germ cell cancer. Ann Oncol 1994;5:355-358.

  14. Leitner SL, Bosl GJ, Bajorunas D. Gonadal dysfunction in patients treated for metastatic germ-cell tumors. J Clin Oncol 1986;4:1500-1505.

  15. Johnson DE, Hainsworth JD, Linde RB. Testicular function following combination with cis-platin, vinblastin and bleomycin. Med Pediatr Oncol 1984;12:233-238.

  16. Kreuser ED, Harsch U, Hetzel WD. Chronic gonadal toxicity in patients with testicular cancer after chemotherapy. Eur J Cancer Clin Oncol 1986;22:289-294.

  17. Booth JD, Merriam GR, Clark RV, et al. Evidence for Leydig cell dysfunction in infertile men with a selective increase in plasma follicle-stimulating hormone. J Clin Endocrinol Metab 1987;64:1194-1198.

  18. Gerl A, Clemm C, Schmeller N, et al. Late relapse of germ cell tumors after cisplatin-based chemotherapy. Ann Oncol 1997;8:41-47.

  19. Travis LB, Beard C, Allan JM, et al. Testicular cancer survivorship: research strategies and recommendations. J Natl Cancer Inst 2010;102:1114-1130.

  20. Abouassaly R, Fossa SD, Giwercman A, et al. Sequelae of Treatment in Longterm Survivors of Testis Cancer. Eur Urol 2011;60:516-526.

  21. Raman JD, Nobert CF, Goldstein M. Increased incidence of testicular cancer in men presenting with infertility and abnormal semen analysis. J Urol 1999;161:1819-1822.

  22. WHO. Laboratory manual for the examination and processing of human semen. 5a ed. 2010.




2020     |     www.medigraphic.com